This result suggests that tamibarotene has significant activity in substantial patients with relapsed APL after ATRA and ATO treatment [107], and a more significant role in the cases that acquire PML mutations associated with the resistance to ATO [108,109]. This evidence concerns the gene PML and acute promyelocytic leukemia.